Drug
Arc 520
Arc 520: highest development phase Phase 2, developed by Arrowhead Pharmaceuticals. 6 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Arrowhead Pharmaceuticals
Trials
| Drug | Phase | Indication |
|---|---|---|
| ARC-520 Injection NCT02349126 | Phase 2 | Chronic Hepatitis B |
| ARC-520 NCT02065336 | Phase 2 | Hepatitis B, Chronic |
| ARC-520 NCT02577029 | Phase 2 | Hepatitis B |
| ARC-520 NCT02452528 | Phase 2 | Chronic Hepatitis B |
| ARC-520 NCT02604212 | Phase 2 | Hepatitis B |
| ARC-520 Injection NCT02738008 | Phase 2 | Hepatitis B |
Latest
No recent events.
Follow Arc 520 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.